Updated:
Celltrion
Celltrion was established in 1991 by Seo Jung-jin as a South Korean biopharmaceutical company. It developed the world's first biosimilar monoclonal antibody...
Celltrion
Celltrion was established in 1991 by Seo Jung-jin as a South Korean biopharmaceutical company. It developed the world's first biosimilar monoclonal antibody and maintains both small-molecule and biologic operations. The company invests across direct secondaries, early-stage seed rounds, and growth equity. It holds controlling stakes in Celltrion Holdings and Celltrion Pharm while operating manufacturing assets in South Korea and the United States. Confirmed positions include long equity in its listed subsidiaries and a planned Global Healthcare Fund targeting biotech companies worldwide. Geographic reach centers on South Korea and North America. Celltrion reports 15,124 million USD in assets and employs staff across headquarters and R&D facilities in Incheon plus commercial offices in Jersey City. It maintains the Celltrion Welfare Foundation, established in 2006, which supports scholarships and medical aid in South Korea. January 2026: Seo Jung-jin addressed the J.P. Morgan Healthcare Conference on U.S. manufacturing expansion and 2027 Nasdaq listing plans. Celltrion operates through a holding-company structure in which Seo Jung-jin controls 98.13 percent of Celltrion Holdings, creating a direct ownership link between the listed operating company and family-controlled vehicles.
General information
Firm type
Corporate Investor
Year founded
1991
Location
Region
Asia
Country
South Korea
City
Incheon
Corporate office
23, Academy-ro, Yeonsu-gu, Incheon, Republic of Korea
Additional offices
Branchburg, NJ, USA · Jersey City, NJ, USA · Songdo, Incheon, Republic of Korea
Principals
Seo Jung-jin
Founder and Chairman
Seo Jin-seok
Co-Chairman and CEO
Seo Jun-seok
Senior Vice Chairman and Head of North America
Sector focus
Frequently asked questions
Who runs investment decisions at Celltrion?
Seo Jung-jin serves as Founder and Chairman. His eldest son Seo Jin-seok acts as Co-Chairman and CEO while younger son Seo Jun-seok heads North American operations.
Does Celltrion participate in fund commitments or only direct deals?
The firm executes direct secondaries and early-stage investments. It also announced plans for a dedicated Global Healthcare Fund.
Where does Celltrion maintain manufacturing and R&D facilities?
Primary sites sit in Incheon, South Korea, including the Global R&D Center opened in 2023. An additional manufacturing plant operates in Branchburg, New Jersey.
What is Celltrion's known posture on co-investments alongside external GPs?
Historical records show Temasek Holdings as a past co-investor in Celltrion itself. Current strategy emphasizes proprietary direct holdings rather than third-party fund commitments.
Does Celltrion maintain philanthropic structures, and how are they separated?
The Celltrion Welfare Foundation was created in 2006. It focuses on youth scholarships and medical assistance for low-income households in South Korea and operates separately from the operating company.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: